Skip to main content Accessibility help
×
Home
Hostname: page-component-cf9d5c678-m9wwp Total loading time: 3.248 Render date: 2021-08-04T14:17:11.379Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": true, "newCiteModal": false, "newCitedByModal": true, "newEcommerce": true, "newUsageEvents": true }

Article contents

EPA-1600 - Celecoxib Add-on to Sertraline in the Therapy of Major Depression: Cytokines and Kynurenine Metabolites

Published online by Cambridge University Press:  15 April 2020

E. Weidinger
Affiliation:
Psychiatry, Ludwig-Maximilians-University, München, Germany
B. Leitner
Affiliation:
Psychiatry, Ludwig-Maximilians-University, München, Germany
S. Fischer
Affiliation:
Psychiatry, Ludwig-Maximilians-University, München, Germany
D.L. Krause
Affiliation:
Psychiatry, Ludwig-Maximilians-University, München, Germany
A.M. Myint
Affiliation:
Psychiatry, Ludwig-Maximilians-University, München, Germany
M.J. Schwarz
Affiliation:
Laboratory Medicine, Ludwig-Maximilians-University, München, Germany
P. Zill
Affiliation:
Psychiatry, Ludwig-Maximilians-University, München, Germany
N. Müller
Affiliation:
Psychiatry, Ludwig-Maximilians-University, München, Germany
Get access

Abstract

Introduction

A proinflammatory state in a subgroup of depressed patients has been reported repeatedly (e.g. increased interleukin-6 and tumour necrosis factor-alpha). COX-2 inhibitors down-regulate increased inflammatory markers and are therefore investigated as an add-on therapy in depression. Proinflammatory cytokines and/or kynurenine metabolites may predict the outcome of treatment with COX-2 inhibitors.

Objectives

To prove or disapprove the hypothesis of a better therapy response in the group of add-on celecoxib to sertraline, particularly in patients with a more pronounced proinflammatory state at baseline. The aim is to find a biological predictor (cytokines and/or kynurenine metabolites) for treatment outcome.

Design

This is a dual-center, randomized, double-blind, placebo-controlled, parallel group phase IIa study. It investigates the mean change in clinical outcome and in serum cytokine and kynurenine levels from baseline to endpoint (week 6) in patients with major depression (HAMD-17 ≥ 22) treated with sertraline plus celecoxib versus sertraline plus placebo for six weeks. 51 depressed patients of both gender, aged between 18 and 60 years without any recent inflammatory disease were enrolled. The study comprises six study visits (6x ratings, 3x blood collections) during six weeks of treatment and a follow-up visit 10 weeks after baseline. Cytokines were measured by Enzyme-linked Immunosorbent Assay (ELISA), kynurenine and its metabolites by High Performance Liquid Chromatography (HPLC).

Results and Conclusion

The study was completed quite recently and the results are in progress.

Type
P25 - Psychoneuroimmunology
Copyright
Copyright © European Psychiatric Association 2014

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)
Submit a response

Comments

No Comments have been published for this article.

Send article to Kindle

To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

EPA-1600 - Celecoxib Add-on to Sertraline in the Therapy of Major Depression: Cytokines and Kynurenine Metabolites
Available formats
×

Send article to Dropbox

To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

EPA-1600 - Celecoxib Add-on to Sertraline in the Therapy of Major Depression: Cytokines and Kynurenine Metabolites
Available formats
×

Send article to Google Drive

To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

EPA-1600 - Celecoxib Add-on to Sertraline in the Therapy of Major Depression: Cytokines and Kynurenine Metabolites
Available formats
×
×

Reply to: Submit a response

Please enter your response.

Your details

Please enter a valid email address.

Conflicting interests

Do you have any conflicting interests? *